Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | UTI | JANX |
|---|---|---|
| Price | $19.89 | $17.92 |
| Change today | ▲ 1.12% | ▲ 6.73% |
| Market cap | $1.10B | $1.10B |
| Return, 3 months | -59.2% | +7.0% |
| Return, year to date | -23.9% | +29.9% |
| Return, 1 year | -34.7% | -26.0% |
| P/E (TTM) | 32.6 | -10.9 |
| P/B | 3.2 | 1.2 |
| P/E percentile vs own 5y | 41st | 46th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +7.2% | – |
| Net profit growth (YoY) | -78.6% | +35.1% |
| Gross margin | 48.1% | – |
| Operating margin | 5.0% | -598.1% |
| Net margin | 3.9% | -427.5% |
| Return on equity | 10.5% | -10.7% |
| Analyst target vs. price | +84.4% | +91.0% |
| Analyst buy share | 86% | 91% |
| RSI (14) | 40 | 56 |
| 30-day volatility | 40.3% | 52.8% |
| Max drawdown, 1 year | -63.9% | -64.9% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
